TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05531825

Intervention type: DEVICE
Intervention: A device for detecting arteriovenous fistula vascular function
Description: An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels

Intervention type: DEVICE
Intervention: A device for detecting arteriovenous fistula vascular function
Description: An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels

Intervention type: DEVICE
Intervention: A device for detecting arteriovenous fistula vascular function
Description: An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels

Intervention type: DEVICE
Intervention: A device for detecting arteriovenous fistula vascular function
Description: An innovative design based on PVDF piezoelectric membrane by combining all kinds of technologies including NB-iot/4G transmission mode to realize real-time monitoring and feedback of the health status of arteriovenous fistula vessels
Study: NCT05671328

Intervention type: OTHER
Intervention: Biological examinations performed on blood and BAL
Description: Direct examination and culture of BAL Galactomannan in serum and BAL Serum 1,3 beta D glucans Aspergillus PCR in BAL
Study: NCT06138795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2389
Description: Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.
Study: NCT06449547

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hospital Anxiety and Depression Scale
Description: Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Study: NCT05320302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]-Lu AF88370
Description: PET ligand in a single intravenous bolus injection
Study: NCT05242523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bergamot scent
Description: The scent of bergamot is fruity and citrusy, with floral hints and spice notes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural wood scent
Description: Wood notes tend to be rich and warm, often forming the base of a scent due to their aromatic weight.
Study: NCT05881278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Description: Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)
Study: NCT05529940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.
Study: NCT06402084

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasound
Description: abdominal ultrasound and lipid profile will be done

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasound
Description: abdominal ultrasound and lipid profile will be done
Study: NCT06497075

Intervention type: DRUG
Intervention: Albendazole 400mg
Description: Single oral dose of Albendazole 400mg tablet

Intervention type: DRUG
Intervention: Albendazole 400mg
Description: Single oral dose of Albendazole 400mg tablet

Intervention type: DRUG
Intervention: Ivermectin 3 MG
Description: Generic ivermectin 3mg tablets given as a single oral dose of 200ug/kg using a dose-pole (height categories: 90-119 cm: 1 tablet , 120-140 cm: 2 tablets, 141-158 cm: 3 tablets or \> 158 cm: 4 tablets)
Study: NCT04968379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous
Study: NCT04878887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IP-DRA vs IP- PRA
Description: Catetherization approach in plane : distal radial artery VS proximal radial artery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: IP-DRA vs IP- PRA
Description: Catetherization approach in plane : distal radial artery VS proximal radial artery
Study: NCT05777018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional recruitment maneuvers
Description: The recruitment maneuver will be performed at 3 predefined time points: 5 minutes after induction of GA (T2), 5 minutes after insufflation of the capnoperitoneum (T3), After the end of surgery and before recovery from anesthesia (T4).~by pressure controlled mode starting with an airway pressure of 15 cmH2O the subsquently changed ( decrease or increase) to provide targeted tidal volume according to each patient, maintaining end-tidal carbon dioxide between 35 to 45 mmHg with 5 cmH2O increments in PEEP until a peak pressure of 30 cmH2O will be achieved. Each PEEP level will be maintained for 5 s. The peak airway pressure will be maintained for 10 s or five breaths and subsequently reduced, followed by maintenance with the previous ventilator settings

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-guided recruitment maneuvers
Description: * Ultrasound guided maneuver will be performed at T2, T3 and T4.~* The recruitment maneuver will be performed under ultrasound guidance until no collapsed lung area is visible. The strategy to increase the airway pressure will be the same as that for the conventional maneuver, although the maximal pressure limit will be 40 cmH2O. The Recruitment maneuvers (RM) will be started searching the pressure level at which the consolidation pattern disappears and progressive lung re-aeration is observed and will be recorded for all patients (the lung's opening pressure).(14) Lung ultrasound examination will be performed every 5 cmH2O increments in PEEP to detect the lung's opening pressure.
Study: NCT05561374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose OKN-007, BID
Description: Participants will be administered low doses of oral OKN-007 two times a day daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose OKN-007, TID
Description: Participants will be administered low doses of oral OKN-007 three times a day daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid-dose OKN-007, TID
Description: Participants will be administered mid doses of oral OKN-007 three times a day daily in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose OKN-007, TID
Description: Participants will be administered high doses of oral OKN-007 three times a day daily in 28-day cycles.
Study: NCT05993039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane Inhalant Product
Description: 1.5-2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane inhalant product
Description: 1-2% adults 0.6-1.5% Children

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol injection
Description: 1mg/kg-mcg/kg/min adults 100-200mcg/kg/min children

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Injection
Description: 0.05-2ug/kg/min adults and children
Study: NCT06094192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
Study: NCT05398926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine (Vero cell), Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.
Study: NCT06094192

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High definition transcranial electrical current stimulation
Description: Low-intensity and safe, noninvasive application of electrical current to the human scalp with the goal of gradually modulating levels of neuronal excitability.
Study: NCT05364606

Intervention type: DEVICE
Intervention: Patient Specific Talus Spacer
Description: Patient Specific Talus Spacer is a solid polished replica of the patient's bone.
Study: NCT06146660

Intervention type: DRUG
Intervention: Mavacamten
Description: According to approved product label
Study: NCT05761392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Precise management
Description: The daily pain state assessments contain three components, the visual analogue scale (VAS) based on pain intensity, time-intensity curve throughout the day, and pain locations. The VAS scores from the first seven post-operative days will be collected as the baseline data. The interventional threshold will be determined by adding 30 mm (if the scale length were 100 mm) to the baseline mean. If participants score above the threshold three times in a row, a warning will be sent to their physicians. A remote meeting will be scheduled and stimulation settings will be adjusted accordingly.
Study: NCT05614115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: is a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06361693

Intervention type: OTHER
Intervention: Auto-preoxygenation
Description: Management is not modified. Routine monitoring (ECG, BP, SpO2). As in care, the patient takes the mask and the respirator is started, delivering an inspired oxygen fraction of 100% (FiO2=1).~Monitoring of : inspired fraction of oxygen, expired fraction of oxygen and end-tidal fraction of carbon dioxide. The ventilator also provides the respiratory rate and tidal volume carried out by the patient.~The fresh gas flow is set by default and will be adjusted to 12l/min for patient comfort.After less than a minute, a normal capnia curve and the presence of an FeO2 value appear. Here, time is standardized to 1 min. In the absence of one of these elements, the caregiver always takes control of preoxygenation.Timer is started, it is T0 min. At T 3min, collection of values and decision-making :~* objectives achieved : end of this sequence.~* objectives not achieved, the caregiver takes control again for an additional 2 minutes in order to seek to achieve an FeO2\>90%.

Intervention type: OTHER
Intervention: APAIS scale
Description: APAIS scale
Study: NCT06640608

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT - Internet Based Cognitive Behavioral Therapy
Description: The study (intervention) group received 6 consecutive sessions utilizing ICBT techniques to overcome Fear of childbirth
Study: NCT06639477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment As Usual
Description: In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: In this trial, all participants will have depression symptoms and will be receiving TAU from their own doctors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Condition
Description: Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Participants receive eight \~40 minute sessions (one per week) with a therapist/health coach. Specific information regarding the nature of the interventions is withheld to protect the scientific integrity of the study design.
Study: NCT06644937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE combined with Acoradine
Description: Transcatheter hepatic arterial chemoembolization (TACE) : the treatment interval was 28 days, the window period was ± 7 days. Subjects received a maximum of 4 TACE treatments; reduced and delayed treatment: laboratory tests were performed before the start of each cycle of TACE, with investigator criteria confirming whether TACE treatment was feasible.~Acoradine: 6 tablets bid, taken after meals for 6 months or until intolerable or progressive disease (starting one month after surgery) .
Study: NCT05753631

Intervention type: PROCEDURE
Intervention: non surgical periodontal treatment
Description: scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated.

Intervention type: PROCEDURE
Intervention: non surgical periodontal treatment
Description: scaling and root planning were applied for non-surgical periodontal treatment i-PRF application: Intravenous blood sample taken from the antecubital vein of the patients was collected in a 10 ml tube and centrifuged at 700 rpm for 3 minutes in a PRF centrifuge device. The PRF obtained from the upper liquid layer formed in the tube was injected subgingival into the deepest point of the pocket after SRP treatment.~Clinical periodontal measurements: plaque index, gingival index, probing depth, clinical attachment level, bleeding on probing, and gingival recession were calculated.~gingival crevicular fluid: Perio papers were placed in the deepest part of the sulcus and left for 30 seconds. After 30 seconds, the paper strips were placed in the periotron device and the volume was calculated.
Study: NCT05659056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib, trastuzumab, paclitaxel-albumin
Description: pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles
Study: NCT06361693

Intervention type: OTHER
Intervention: Visual analog anxiety scale (VAS-A)
Description: Visual analog anxiety scale (VAS-A)

Intervention type: OTHER
Intervention: Visual analog comfort scale (VAS-C)
Description: Visual analog comfort scale (VAS-C)
Study: NCT04824729

Intervention type: PROCEDURE
Intervention: Lower limb revascularization
Description: French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.

Intervention type: PROCEDURE
Intervention: Lower limb revascularization
Description: French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
Study: NCT04581759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC device (IPC-906X)
Description: Patients in the RIPC group will have five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm twice a day after Mechanical Thrombectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: foundational treatment
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: foundational treatment
Description: foundational treatment, including free radical elimination in the acute stage, blood pressure and blood glucose stabilization, and antiplatelet (aspirin or/and clopidogrel ) and lipid-lowering (statins) drugs
Study: NCT04464603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InterFACE (mHealth tool)
Description: Participants will be asked to perform consecutively two 20-min highly realistic, scripted CPR scenarios (first: PALS-based scenario, second: ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and the 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to Arm A will not be allowed to use any other cognitive support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional methods
Description: Participants will be asked to perform consecutively two 20-min scripted CPR scenarios (PALS and ATLS-based scenario) on a high-fidelity WiFi manikin.~Within each scenario, 3 separate freeze periods will occur at random points in time to assess the shared and complementary Situation Awareness of each team member individually regarding the CPR in progress at that exact moment in time. The scenarios will be standardized to strictly follow the 2018 AHA algorithms and 2018 ATLS guidelines.~Both scenarios will be completed in the same order and the procedure will be standardized across all teams to follow the same chronological progression and range of difficulty in order to ensure that each participant is exposed to exactly the same case, with similar challenges in technical and non-technical skills.~Participants allocated to group B will be allowed to use the PALS pocket reference cards and a conventional calculator, but not any other cognitive support or mHealth tool.
Study: NCT05973331

Intervention type: OTHER
Intervention: Pancreatic Cancer Risk Model (PRISM)
Description: A neural network model (PrismNN) and a logistic regression model (PrismLR) that use routinely collected EHR data to stratify individuals from the general population into PDAC risk groups
Study: NCT05245955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessments of the hand sensory function with the ReHapticKnob
Description: During the assessment sessions with the ReHapticKnob, subjects sit comfortably on a chair in front of a screen and place the fingers of the hand on the handles of the device. The different assessments consist of moving the hand or forearm of the subjects to two different positions and asking the subject to discriminate between them (discrimination thresholds for the amplitude of grasping and forearm pronosupination positions), of passively moving the hand or forearm of the subject at low velocities and asking the subject to say when he/she detects the movement (detection thresholds for passive movements), or of rendering two objects with different stiffness and asking the subject to discriminate between them (discrimination thresholds for the stiffness of objects pinched with the hand).